NYMOX-PHARMA!Endeckt(350%)
negativen Auswirkungen auf uns Aktionäre. Weniger Aktionärsschutz, mehr Vorteile
für die Gesellschaft bzw. Vorstände!
--------------------------------
On July 31, 2015 Nymox Pharmaceutical Corporation received formal approvals for its change of domicile to the Bahamas was effective.
At the Special Shareholders Meeting of Nymox on April 23, 2015 there was a 94% majority shareholder vote in favor of the Company's change of domicile to the Bahamas. Subsequent to the majority vote in favor, on July 31, 2015 the Company was informed that it has received formal approval from Corporations Canada. The Company's Management are located in Bahamas, the U.S. and Europe. The Company currently maintains offices in the Bahamas, the U.S. and Canada.
http://www.sec.gov/Archives/edgar/data/1018735/...8/nymox6k150804.htm
"NX-1207 is a novel treatment for BHP. The competition for BPH treatments is intense and involves many of the big pharma players. Currents treatments involve radiation and drugs therapies that usually involve catheterization or introduction through the femoral artery to deliver the treatment directly to the prostate. The NYMX therapy involves an injection that can be done in an urologist’s office.
The market for NX-1207 is huge and FDA approval will create a demand for the product. Though the drug is designed for low intensity BPH there seems to be some suggestion that it can also improve the efficient of some of the more invasive therapies used to treat more aggressive prostate issues.
The launch of NX-1207 would go a long way toward development of the company’s other products. Treatments for e-coli, staph infections, UTI and Alzheimer’s represent the opportunity for huge NYMX growth.
Despite impressive scores for growth and momentum, NYMX is rated a Hold because
its low value score implies it might be overvalued.
• Momentum: NYMX is a top performer with respect to momentum, as evidenced by
a Sabrient Momentum Score of 98.4. Stocks with high momentum scores typically
continue their bullish price behavior at least in the very short term. The score
reflects price, earnings, and group momentum.
• Growth: NYMX has a Sabrient Growth Score of 84.4.
• Value: With a Sabrient Value Score of 10.5, NYMX is overvalued at its current
price.
• Timeliness: NYMX has a Sabrient Timeliness Score of 89.6. This measures
technical strength based on short-term and long-term price performance and
long-term group strength.
Gru$$ KH
Optionen
| Boardmail an "Kurshellseher" |
Wertpapier: Nymox Pharmaceutical |
Optionen
| Boardmail an "Kurshellseher" |
Wertpapier: Nymox Pharmaceutical |
Optionen
| Boardmail an "Kurshellseher" |
Wertpapier: Nymox Pharmaceutical |
bewußt sein, daß Zocker versuchen, sich die augenblickliche Situation zunutze zu machen. Es kann ja jede Woche die NEWS über den Zulassungsantrag eintrudeln.
Bis Ende des Jahres sehe ich ganz andere Kurse als heute. Ist ja ein US Wert und
die US Anleger sind kauffreudiger als unsere deutschen Aktionäre.
Optionen
| Boardmail an "Kurshellseher" |
Wertpapier: Nymox Pharmaceutical |
19 $ .
Optionen
| Boardmail an "Kurshellseher" |
Wertpapier: Nymox Pharmaceutical |
News vom 27.7.15
"The Company now intends to meet with authorities and to proceed to file where possible in due course for regulatory approvals for fexapotide triflutate in various jurisdictions and territories."
http://www.nymox.com/resources/content/d244.pdf
1. Schritt: FDA prüft, ob sie prüft. Dafür sind 2 Monate vorgesehen;
2. Schritt: FDA Prüfung. Dafür sind 9-12 Monate veranschlagt;
3. Schritt: FDA gibt midterm-review. Ein vorläufiges Ergebnis, ob die Zulassung erfolgen wird, kann also bereits nach 6 Monaten vorliegen.
Dann kann Nymox bereits mit dem Vertrieb beginnen.
Im nachhinhein ist es klar. 55$. Aber mitten im Lauf? Innerhalb von 3 Tagen?
Ich habe nur staunend zuschauen können - leider !!
Optionen
| Boardmail an "Kurshellseher" |
Wertpapier: Nymox Pharmaceutical |
hier muß man sich allerdings registrieren:
Healthcare Insider Roundup: Nymox Pharmaceutical Corporation & More
http://seekingalpha.com/article/...utical-corporation-and-more?page=5
sinkendes Short Interesse im August:
http://sleekmoney.com/...es-large-drop-in-short-interest-nymx/455473/
Focus Ticker: NYMX
In my very first LCP Daily Insider Note, I observed that Nymox Pharmaceutical Corporation (NASDAQ:NYMX) was one of a few particularly interesting long-opportunities to watch in the coming weeks. Here, I follow up on that claim by covering the basics of the company, as well as recent insider events, and finally, by exploring potential future catalysts that could be driving share price fluctuations today.
But before we begin, let's face it: with an intraday market cap just a hair over $91 million, Nymox is not exactly a household name. At least, not yet. So for all you investment experts out there, please bear with me as I summarize the basics of what I believe is a seriously underappreciated nano cap investment opportunity in the healthcare sector.
Nymox Pharmaceutical Corporation is a Canada-based biopharmaceutical company that specializes in the research and development of novel drugs and diagnostic products. Their leading products under development include NX-1207, a proprietary treatment for enlarged prostate or benign prostatic hyperplasia (NYSE:BHP); NXC-4720, an anti-bacterial agent which is designed to treat E. Coli O157:H7 bacterial contamination in food products; NXB-4221 for the treatment of chronic urinary tract infections; NXB-5886 for the treatment of streptococcal infection; and NXT-1021 for the treatment of staphylococcal infection.
In addition to its ongoing research and development campaigns, the company currently markets NicAlert, a test to determine smoking status, and TobacAlert, a home test that determines one's level of exposure to second hand smoke. Both diagnostics are marketed and distributed in North America, Europe, and Asia. TobacAlert is also marketed online at tobacalaert.com.
Company Profile
Nymox Pharmaceutical Corporation is a Canada-based biopharmaceutical company.
The Company focuses on developing NX-1207, a treatment for benign prostatic
hyperplasia (BPH) which is in Phase III trials in the United States.
Earnings and Revenue Update: For the quarter ended June 30, 2015, Nymox
Pharmaceutical Corp reported earnings of $-23.3 million or $-0.63 per share
compared with $1.6 million or $0.04 per share for the prior quarter and $-0.8
million or $-0.02 per share for the same quarter one year ago. Revenues were $0.1
million for the quarter ended June 30, 2015 compared with $2.6 million for the prior
quarter and $0.8 million for the same quarter one year ago. Last twelve months'
earnings were $-0.62 per share compared with $-0.17 per share a year ago. Last
twelve months' revenues were $4.1 million compared with $3.2 million a year ago.
"Gemäß den US-Richtlinien muss die FDA innerhalb von 60 Tagen darüber entscheiden, ob der Zulassungsantrag zum Review angenommen wird (acceptance to file). Mit der Annahme des Antrags bestätigt die FDA seine Vollständigkeit und geht in den folgenden Monaten in eine intensive Prüfungsphase, die normalerweise innerhalb von 9-12 Monaten ab Einreichung beendet ist. Etwa sechs Monate nach dem "acceptance to file" wird ein Zwischenbericht ("mid-term review") der FDA erwartet, nach dem die Erteilung der Zulassung bereits weitgehend feststehen kann."
http://inpublic.globenewswire.com/2015/07/13/...v6TvRrVSCy!1331056414
benignes Prostatasyndrom, benigne Prostatahyperplasie, BPH
http://www.urologie.hexal.de/prostatavergroesserung-bph/ueberblick/
Optionen
| Boardmail an "Kurshellseher" |
Wertpapier: Nymox Pharmaceutical |
10:02:32 $4.22 100
10:02:09 $4.227 948
10:02:09 $4.22 2,950
10:02:09 $4.24 100
10:02:05 $4.25 360
http://www.nasdaq.com/de/symbol/nymx/real-time
Optionen
| Boardmail an "Kurshellseher" |
Wertpapier: Nymox Pharmaceutical |